Nineteen patients with HER2/Neu-positive tumors (16 osteosarcomas, one Ewing sarcoma, one primitive neuroectodermal tumor, and one desmoplastic small round cell tumor) were treated with the HER2 CAR T cells with the T cell dose ranging from 1 × 104/m2 to 1 × 108/m2. Here, ERBB2 is linked to osteosarcoma.